Source: International Congress 2018 – Identification of therapeutic targets for asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Magalhães (Belo Horizonte , Brazil), M. Rodrigues-Machado (Belo Horizonte , Brazil), J. Gregório (Belo Horizonte , Brazil), K. Gonzaga (Belo Horizonte , Brazil), P. Cassini (Belo Horizonte , Brazil), L. Barcelos (Belo Horizonte , Brazil), R. Santos (Belo Horizonte , Brazil), M. Campagnole-Santos (Belo Horizonte , Brazil). Inhaled formulation of angiotensin-(1-7) produces lung protective effects in a model of chronic asthma.. 981

Member's Comments

No comment yet.

Related content which might interest you: Protective effect of inhaled glucocorticosteroids on COPD model. Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair Year: 2020 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Effects of treatment with angiotensin-(1-7) on antigen sensitization of murine experimental model of asthma Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Additive effect of targeted lung denervation plus drug in patients with COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Late-breaking abstract: Inhaled calcium based dry powder inhibits rhinovirus-induced inflammation and exacerbation in a mouse model of allergic airway inflammation Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Inhaled budesonide suppresses airway and systemic eosinophilic inflammation in COPD. No predictive value of a prednisolone test treatment Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005 Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice Source: Annual Congress 2008 - Novel mechanisms in the pathogenesis of pulmonary inflammation Year: 2008 The effects of oral corticosteroid treatment (OCS) on sequential lung function tests in a cohort of patients with acute hypersensitivity pneumonitis (AHP) Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020